



Rabbit Anti-AKT1 antibody

SLM-52010R

Product Name AKT1

Chinese Name 蛋白激酶 BRecombinant rabbit monoclonal anti

Alias

AKT 1; AKT; AKT1; AKT-1; AKT1_HUMAN; C AKT; cAKT; MGC9965; MGC99656; Oncoprotein; PKB; PKB alpha; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene; RAC Alpha; RAC alpha serine/threonine protein kinase; RAC; RAC PK Alpha; Rac protein kinase; Serine/Threonine Protein Kinase; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; vakt; thymoma viral oncogene homolog 1; vAKT Murine Thymoma Viral Oncogene Homolog 1.

Research Area

Tumour Cell biology Neurobiology Signal transduction Apoptosis Kinases and Phosphatases

Immunogen Species

Rabbit

Clonality

Monoclonal

Clone NO.

11F2

React Species

Human,Mouse,Rat

Applications

WB=1:2000-10000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,Flow-Cyt=1:50-100,ICC (Paraffin sections need antigen repair)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.

Theoretical molecular weight

56kDa

Cellular localization

The nucleus cytoplasmic The cell membrane

Form

Liquid

Concentration

1mg/ml

immunogen

Recombinant human AKT1 protein

Lsotype

IgG

Purification

affinity purified by Protein A

Buffer Solution

1M TBS(pH7.4) with 1% BSA, 3% Proclin300 and 50% Glycerol.

Storage

Shipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Attention

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

PubMed

[PubMed](#)

The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. Activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system, AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene. [RefSeq, Jul 2011]

**Product
Detail**

Function:

AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) catalyzing the phosphorylation of a wide range of substrates, and which regulate many processes including metabolism, proliferation, cell survival, growth, differentiation, and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one of the mechanisms by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of p53 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity and thereby prevents oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-318', and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP response element binding protein). The phosphorylation of CREB1 induces the binding of other transcription factors that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIK3CA at 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is a substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT has a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of neuronal integration during adult neurogenesis, including correct neuron positioning, dendritic development and synaptic maturation.

synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-308' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate substrates. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRSF2 and ACIN1 and promotes its nuclear translocation. Inhibits RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. AKT1-specific substrates have been recently identified, including palladin (PALLD), which plays a role in phosphorylation modulates cytoskeletal organization and cell motility; prohibitin (PHB), playing a role in cell metabolism and proliferation; and CDKN1A, for which phosphorylation at 'Thr-145' leads to its release from CDK2 and cytoplasmic relocalization. These recent findings indicate that the AKT1 has a more specific role in cell motility and proliferation. Phosphorylates CLK2 thereby controlling cell cycle progression after ionizing radiation.

Subunit:

Interacts (via the C-terminus) with CCDC88A (via its C-terminus). Interacts with GRB10; the interaction is dependent on GRB10 phosphorylation thus promoting YWHAE-binding. Interacts with AGAP2 (isoform 2); the interaction occurs in the presence of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1A AND TCL1B. Interacts with CDKN1B; the interaction phosphorylates CDKN1B leading to 14-3-3 binding and cell-cycle progression. Interacts with MAP3K5 and TRAF6. Interacts with BCL2L1, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts (via the C-terminus) with TRAF6 (via C-terminus). Interacts with and phosphorylated by PDPK1.

Subcellular Location:

Cytoplasm. Nucleus. Cell membrane. Note=Nucleus after activation by integrin-linked protein kinase. Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TRAF6 leads to its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Thr-309 leading to its activation and the activated form translocates to the nucleus.

Tissue Specificity:

Expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.

Post-translational modifications:

O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating phosphorylation at Thr-308 via direct interaction between AKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with activating phosphorylation at this site.

Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates Akt on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated Akt localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylation on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isozyme (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells. Ser-473 phosphorylation is enhanced by signaling through activated FLT3. Dephosphorylated Akt is phosphorylated on Ser-473 by PP2A phosphatase. The phosphorylated form of PPP2R5B is required for bridging Akt and PP2A phosphatase.

Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading to its degradation by the proteasome. Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced Akt1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated to the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome. Also ubiquitinated by TRIM13 leading to its proteasomal degradation.

Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases EP300 and KAT2B. Acetylation reduces phosphorylation and inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1 and SIRT6. SIRT1-mediated deacetylation relieves the inhibition.

DISEASE:

Defects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common form of breast cancer originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histology. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral occurrence. Mutations at more than one locus can be involved in different families or even in the same case.

Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].

Note=Genetic variations in AKT1 may play a role in susceptibility to ovarian cancer.

Defects in AKT1 are a cause of Proteus syndrome (PROTEUSS) [MIM:176920]. A highly variable disorder of asymmetric and disproportionate overgrowth of body parts, connective tissue nevi, epidermal dysregulation, dysregulated adipose tissue, and vascular malformations. Many features of Proteus syndrome overlap with overgrowth syndromes.

Similarity:

Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.

Contains 1 AGC-kinase C-terminal domain.

Contains 1 PH domain.

Contains 1 protein kinase domain.

SWISS:

P31749

Gene ID:

207

Database links:

[Entrez Gene: 207](#) Human

[Entrez Gene: 11651](#) Mouse

[Entrez Gene: 24185](#) Rat

[Omim: 164730](#) Human

[SwissProt: O57513](#) Chicken

[SwissProt: P31749](#) Human

[SwissProt: P31750](#) Mouse


[SwissProt: P47196](#) Rat

[Unigene: 525622](#) Human

[Unigene: 6645](#) Mouse

[Unigene: 11422](#) Rat

**Product
Picture**



Sample:

Cerebrum (Mouse) Lysate at 40 ug

Lung (Mouse) Lysate at 40 ug

Heart (Mouse) Lysate at 40 ug

HeLa(Human) Cell Lysate at 30 ug

NIH/3T3(Mouse) Cell Lysate at 30 ug

A549(Human) Cell Lysate at 30 ug


HepG2(Human) Cell Lysate at 30 ug

Primary: Anti- AKT1 (SLM-52010R) at 1/1000 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 56 kD

Observed band size: 56 kD



Sample:

Lane 1: Cerebrum (Mouse) Lysate at 40 ug

Lane 2: Thymus (Mouse) Lysate at 40 ug

Lane 3: Heart (Mouse) Lysate at 40 ug

Lane 4: Lung (Mouse) Lysate at 40 ug

Lane 5: NIH/3T3 (Mouse) Cell Lysate at 30 ug

Lane 6: Cerebellum (Rat) Lysate at 40 ug

Lane 7: Thymus (Rat) Lysate at 40 ug

Lane 8: Heart (Rat) Lysate at 40 ug

Lane 9: MCF-7 (Human) Cell Lysate at 30 ug

Lane 10: Hela (Human) Cell Lysate at 30 ug

Lane 11: U937 (Human) Cell Lysate at 30 ug


Lane 12: A549 (Human) Cell Lysate at 30 ug

Primary: Anti- AKT1 (SLM-52010R) at 1/1000 dilution


Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 59 kD

Observed band size: 59 kD




Paraformaldehyde-fixed, paraffin embedded (rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Block non-specific binding with PBS buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (AKT1) Monoclonal Antibody (AKT1) Monoclonal Antibody Unconjugated (SLM-52010R) at 1:200 overnight at 4°C, followed by operating according to SLM-52010R (sp-0023) instructions and DAB staining.




Paraformaldehyde-fixed, paraffin embedded (mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Block non-specific binding with PBS buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (AKT1) Monoclonal Antibody (AKT1) Monoclonal Antibody Unconjugated (SLM-52010R) at 1:200 overnight at 4°C, followed by operating according to SLM-52010R (sp-0023) instructions and DAB staining.


(sp-0023) instructions and DAB staining.




Paraformaldehyde-fixed, paraffin embedded (rat pancreas); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Block non-specific binding with normal goat serum in PBS buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (AKT1) Monoclonal antibody (SLM-52010R) at 1:200 overnight at 4°C, followed by operating according to S (sp-0023) instructions and DAB staining.




Paraformaldehyde-fixed, paraffin embedded (rat heart); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Block non-specific binding by normal goat serum (normal goat serum) at 37°C for 30min; Antibody incubation with (AKT1) Monoclonal Antibody (AKT1) Monoclonal Antibody Unconjugated (SLM-52010R) at 1:200 overnight at 4°C, followed by operating according to SLM-52010R (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (rat lung); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Block non-specific binding by normal goat serum (normal goat serum) at 37°C for 30min; Antibody incubation with (AKT1) Monoclonal Antibody (AKT1) Monoclonal Antibody Unconjugated (SLM-52010R) at 1:200 overnight at 4°C, followed by operating according to SLM-52010R (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (mouse pancreas); Antigen retrieval by boiling in 100mM Tris-EDTA buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Block non-specific binding by 10% normal goat serum in Tris-EDTA buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (AKT1) Monoclonal antibody (SLM-52010R) at 1:200 overnight at 4°C, followed by operating according to SLM-52010R (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (mouse lung); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Block non-specific binding by 3% normal goat serum in PBS buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (AKT1) Monoclonal Antibody (SLM-52010R) at 1:200 overnight at 4°C, followed by operating according to S (sp-0023) instructions and DAB staining.